D-aspartate caged with the photosensitive 4-methoxy-7-nitroindolinyl group. Photolyzed by UV light with a quantum efficiency of 0.09 at pH 7.4. Agonist at NMDA receptors and EAAT substrate.
Sold under license from the UK Medical Research Council
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 309.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.23 mL||16.17 mL||32.33 mL|
|5 mM||0.65 mL||3.23 mL||6.47 mL|
|10 mM||0.32 mL||1.62 mL||3.23 mL|
|50 mM||0.06 mL||0.32 mL||0.65 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Huang et al (2005) Synthesis and characterization of 4-methoxy-7-nitroindolinyl-D-aspartate, a caged compound for selective activation of glutamate transporters and N-methyl-D-aspartate receptors in brain tissue. Biochemistry 44 3316 PMID: 15736942
If you know of a relevant reference for MNI-caged-D-aspartate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MNI-caged-D-aspartate NMDA agonists Glutamate Receptors N-Methyl-D-Aspartate iGluR Ionotropic Caged Compounds EAAT excitatory amino acid transporters 4-Methoxy-7-nitroindolinyl-caged-D-aspartate NMDA Receptors
Citations for MNI-caged-D-aspartate
Citations are publications that use Tocris products.
Currently there are no citations for MNI-caged-D-aspartate. Do you know of a great paper that uses MNI-caged-D-aspartate from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.